LV12606B - OXIMINOALAL ACID DERIVATIVES - Google Patents

OXIMINOALAL ACID DERIVATIVES Download PDF

Info

Publication number: LV12606B
Authority: LV; Latvia
Prior art keywords: optionally substituted; group; hydrogen; ring; ethyl acetate
Prior art date: 1998-05-11

Application number

LVP-00-148A

Other languages

English (en)

Latvian (lv)

Other versions

LV12606A (lv

Inventor

Yu Momose

Hiroyuki Odaka

Hiroshi Imoto

Hiroyuki Kimura

Junichi Sakamoto

Original Assignee

Takeda Chemical Industries, Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-11

Filing date

2000-11-01

Publication date

2001-05-20

2000-11-01 Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.

2001-01-20 Publication of LV12606A publication Critical patent/LV12606A/xx

2001-05-20 Publication of LV12606B publication Critical patent/LV12606B/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

LVP-00-148A 1998-05-11 2000-11-01 OXIMINOALAL ACID DERIVATIVES LV12606B (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP12792198		1998-05-11
JP12792298		1998-05-11
PCT/JP1999/002407 WO1999058510A1 (en)	1998-05-11	1999-05-10	Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity

Publications (2)

Publication Number	Publication Date
LV12606A LV12606A (lv)	2001-01-20
LV12606B true LV12606B (en)	2001-05-20

Family

ID=26463748

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-00-148A LV12606B (en)	1998-05-11	2000-11-01	OXIMINOALAL ACID DERIVATIVES

Country Status (27)

Country	Link
US (3)	US6251926B1 (no)
EP (2)	EP1077957B1 (no)
JP (1)	JP2000198772A (no)
KR (1)	KR100388120B1 (no)
CN (1)	CN1148361C (no)
AR (1)	AR029876A1 (no)
AT (1)	ATE272625T1 (no)
AU (1)	AU766831B2 (no)
BR (1)	BR9910371A (no)
CA (1)	CA2331879A1 (no)
CO (1)	CO5040066A1 (no)
DE (1)	DE69919156T2 (no)
ES (1)	ES2226377T3 (no)
HK (1)	HK1034972A1 (no)
HU (1)	HUP0103714A3 (no)
ID (1)	ID28699A (no)
IL (1)	IL139470A0 (no)
LV (1)	LV12606B (no)
MY (1)	MY123337A (no)
NO (1)	NO317426B1 (no)
NZ (1)	NZ508066A (no)
PE (1)	PE20000625A1 (no)
PL (1)	PL344002A1 (no)
PT (1)	PT1077957E (no)
RU (1)	RU2213738C2 (no)
SK (1)	SK16412000A3 (no)
WO (1)	WO1999058510A1 (no)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK16412000A3 (sk) *	1998-05-11	2001-08-06	Takeda Chemical Industries, Ltd.	Deriváty kyseliny oxyiminoalkánovej
TWI249401B (en) *	1999-04-14	2006-02-21	Takeda Chemical Industries Ltd	Agent for improving ketosis
PT1206457E (pt)	1999-08-27	2004-03-31	Lilly Co Eli	Derivados de diaril-oxa(tia)zol e seu uso como moduladores dos ppars
DE19948126A1 (de) *	1999-10-06	2001-04-12	Max Delbrueck Centrum	Pharmazeutisches Mittel zur Behandlung von Kachexie und/oder kardiogenem Schock
AR031078A1 (es)	1999-10-29	2003-09-10	Takeda Pharmaceutical	Compuesto acido (e)-4-[4-(5-metil-2-fenil-4-oxalilmetoxi)benziloxiimino]-4-fenilbutirico cristalino, composicion farmaceutica que lo comprende y su uso para fabricar esta ultima.
CN1407969A (zh) *	1999-10-29	2003-04-02	武田药品工业株式会社	氧亚氨基链烷酸衍生物的制备方法
HUP0203837A2 (hu) *	1999-11-10	2003-03-28	Takeda Chemical Industries, Ltd.	Testtömegnövekedést gátló szerek
MXPA02004647A (es)	1999-11-10	2002-10-31	Takeda Chemical Industries Ltd	Compuestos heterociclicos de 5 miembros que contienen nitrogeno.
WO2001034579A1 (fr) *	1999-11-10	2001-05-17	Takeda Chemical Industries, Ltd.	Derives d'acide alcoxyiminoalcanoique
EP1277730A4 (en) *	2000-03-28	2005-03-16		HEMMER OF NEOVASCULARIZATION
WO2002014291A1 (en) *	2000-08-11	2002-02-21	Nippon Chemiphar Co.,Ltd.	PPARδ ACTIVATORS
PE20020617A1 (es) *	2000-08-22	2002-08-05	Novartis Ag	Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
US20060089389A1 (en) *	2000-08-22	2006-04-27	Malcolm Allison	Combination
DE60139025D1 (de)	2000-12-28	2009-07-30	Takeda Pharmaceutical	Alkansäurederivate, verfahren zu deren herstellung und deren verwendung
EP1394154A4 (en)	2001-03-23	2005-05-18	Takeda Pharmaceutical	HETEROCYCLIC DERIVATIVE WITH FIVE MEMBERS OF ALKANOIC ACID
WO2002087580A1 (fr) *	2001-04-25	2002-11-07	Takeda Chemical Industries, Ltd.	Promoteurs d'expression d'abc
WO2003059372A2 (en) *	2001-12-29	2003-07-24	Novo Nordisk A/S	Combined use of a glp-1 compound and a modulator of diabetic late complications
TWI343915B (en) *	2002-10-07	2011-06-21	Hoffmann La Roche	Chirale ppar agonists
US8168233B2 (en) *	2002-10-18	2012-05-01	Amylin Pharmaceuticals, Inc.	Treatment of pancreatitis with amylin
WO2004041266A1 (ja)	2002-11-08	2004-05-21	Takeda Pharmaceutical Company Limited	受容体機能調節剤
WO2004053103A2 (en) *	2002-12-11	2004-06-24	University Of Massachusetts	METHOD OF INTRODUCING siRNA INTO ADIPOCYTES
US7790681B2 (en) *	2002-12-17	2010-09-07	Amylin Pharmaceuticals, Inc.	Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US20040209803A1 (en) *	2002-12-19	2004-10-21	Alain Baron	Compositions for the treatment and prevention of nephropathy
US7582662B2 (en) *	2002-12-27	2009-09-01	Takeda Pharmaceutical Company Limited	Body weight gain inhibitor
JP5140881B2 (ja) *	2003-09-17	2013-02-13	要川杉	医薬組成物
AU2005217641B2 (en) *	2004-02-24	2008-02-14	Irm Llc	Immunosuppressant compounds and compositions
EP1731170A1 (en) *	2004-03-29	2006-12-13	Sankyo Company, Limited	Therapeutic agent for diabetes containing insulin resistance improving agent
EP1731505B1 (en)	2004-03-30	2015-01-14	Takeda Pharmaceutical Company Limited	Alkoxyphenylpropanoic acid derivatives
CA2568640C (en)	2004-06-04	2011-08-09	Teva Pharmaceutical Industries Ltd.	Pharmaceutical composition containing irbesartan
EP1790338A4 (en) *	2004-09-13	2007-12-12	Santen Pharmaceutical Co Ltd	THERAPEUTIC AGENT FOR KERATOCONJUNTIVA DISEASES
US7556933B2 (en) *	2004-10-01	2009-07-07	Luminultra Technologies Ltd.	Reagent system and process for adenosine triphosphate monitoring
EP2308839B1 (en)	2005-04-20	2017-03-01	Takeda Pharmaceutical Company Limited	Fused heterocyclic compounds
EP1876179B1 (en)	2005-04-28	2015-03-25	Takeda Pharmaceutical Company Limited	Thienopyrimidone compounds
WO2006126514A1 (ja)	2005-05-27	2006-11-30	Shionogi & Co., Ltd.	イソキサゾール骨格を有するアリール酢酸誘導体
MY152185A (en)	2005-06-10	2014-08-29	Novartis Ag	Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
US7491414B2 (en) *	2005-10-12	2009-02-17	Gaia Herbs, Inc.	Anti-inflammatory substances extracted from Echinacea
JPWO2008136428A1 (ja)	2007-04-27	2010-07-29	武田薬品工業株式会社	含窒素５員複素環化合物
US8349886B2 (en)	2008-04-16	2013-01-08	Takeda Pharmaceutical Company Limited	Nitrogenated 5-membered heterocyclic compound
WO2010011302A1 (en) *	2008-07-22	2010-01-28	Chdi, Inc.	Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2010016552A1 (ja)	2008-08-07	2010-02-11	武田薬品工業株式会社	過敏性腸症候群治療薬
CA2782776A1 (en)	2008-12-04	2010-06-10	Ikfe Gmbh	Biomarkers for atherosclerosis
WO2010067207A1 (en)	2008-12-11	2010-06-17	Ikfe Gmbh	Biomarkers for insulin sensitizer drug response
WO2010076655A1 (en)	2008-12-30	2010-07-08	Ikfe Gmbh	Biomarkers for adipose tissue activity
EP2382475A2 (en)	2009-01-07	2011-11-02	IKFE GmbH	Biomarkers for appetite regulation
CN102875548A (zh) *	2011-07-14	2013-01-16	中国科学院大连化学物理研究所	一类基于肟的通过[2+2+2]环加成合成吡啶衍生物的方法
WO2013033085A1 (en)	2011-08-30	2013-03-07	Stephen Martin Courtney	Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA201490279A1 (ru)	2011-08-30	2014-08-29	Схди Фаундейшн, Инк.	Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
US20150004144A1 (en)	2011-12-02	2015-01-01	The General Hospital Corporation	Differentiation into brown adipocytes
EP2871179A4 (en)	2012-07-03	2016-03-16	Ono Pharmaceutical Co	CONNECTION WITH AGONISTIC EFFECT ON THE SOMATOSTATIN RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
HUE043374T2 (hu)	2013-09-30	2019-08-28	Ono Pharmaceutical Co	Vegyület, amelynek van szomatosztatin receptor agonista aktivitása és annak gyógyszerészeti felhasználása
WO2015107541A1 (en) *	2013-12-16	2015-07-23	Cadila Healthcare Limited	Oximino derivatives for the treatment of dyslipidemia
CN114588157A (zh)	2014-07-17	2022-06-07	Chdi基金会股份有限公司	用于治疗hiv相关病症的方法和组合物
FR3042903B1 (fr) *	2015-10-21	2017-12-08	Commissariat Energie Atomique	Utilisation d'acides hydroxyiminoalcanoiques comme agents anti-nitreux dans des operations de desextraction reductrice du plutonium
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists
US20200000816A1 (en)	2017-02-08	2020-01-02	Ono Pharmaceutical Co., Ltd.	Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
EP4268676A3 (en)	2019-02-21	2024-02-07	Steelcase Inc.	Body support assembly and methods for the use and assembly thereof
US11357329B2 (en)	2019-12-13	2022-06-14	Steelcase Inc.	Body support assembly and methods for the use and assembly thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU177578B (en)	1976-08-27	1981-11-28	Chinoin Gyogyszer Es Vegyeszet	Process for preparing new 0-/3-amino-2-hydroxy-propyl/-amidoxime derivatives
JPS5849382A (ja)	1981-09-18	1983-03-23	Kyowa Hakko Kogyo Co Ltd	β−ラクタム化合物
JPS59167576A (ja)	1983-03-15	1984-09-21	Kyowa Hakko Kogyo Co Ltd	β−ラクタム化合物
JPS6277391A (ja)	1984-12-21	1987-04-09	Mochida Pharmaceut Co Ltd	セフアロスポリン誘導体、その製法およびそれらを有効成分とする抗菌剤
JPS62158290A (ja) *	1985-12-28	1987-07-14	Banyu Pharmaceut Co Ltd	新規セフアロスポリン誘導体
US4698338A (en)	1986-02-19	1987-10-06	Eli Lilly And Company	7[2-(2-aminothiazol-4-yl)-2-benzyloximino]acetamido-3[4-alkyl-5-oxo-6-hydroxy-3,4-dihydro-1,2,4-triazin-3-yl]thiomethyl cephalosporins
US5750532A (en) *	1986-12-10	1998-05-12	Schering Corporation	Pharmaceutically active compounds
JPH0277391A (ja)	1988-09-14	1990-03-16	Suzuki Motor Co Ltd	水ジェット推進船のビルジ水排水装置
ATE169616T1 (de)	1988-11-21	1998-08-15	Zeneca Ltd	Zwischenverbindungen zur herstellung von fungiziden
EP0400805A1 (en)	1989-04-25	1990-12-05	Toshiyasu Ishimaru	Cephalosporin compounds and their use
JPH03115272A (ja) *	1989-10-19	1991-05-16	Banyu Pharmaceut Co Ltd	マンデル酸誘導体およびその製法
IE912046A1 (en) *	1990-06-18	1991-12-18	Fujisawa Pharmaceutical Co	New polypeptide compound and a process for preparation¹thereof
ATE161007T1 (de) *	1990-06-27	1997-12-15	Basf Ag	O-benzyl-oximether und diese verbindungen enthaltende pflanzenschutzmittel
JPH04112890A (ja) *	1990-09-04	1992-04-14	Ajinomoto Co Inc	新規チアゾール誘導体及び該誘導体を含有する抗菌剤
EP0486011A3 (en) *	1990-11-16	1992-07-15	Fujisawa Pharmaceutical Co., Ltd.	Pharmaceutical composition against pneumocystis carinii
JP2691679B2 (ja)	1992-07-21	1997-12-17	小野薬品工業株式会社	オキシム誘導体およびそれを含有する医薬品
US5512581A (en) *	1994-07-18	1996-04-30	Abbott Laboratories	Iminoxycarboxylates and derivatives as inhibitors of leukotriene biosynthesis
CZ261095A3 (en)	1994-10-07	1996-04-17	Sankyo Co	Oxime derivatives, process of their preparation, pharmaceutical composition containing thereof and their use
CH689228A5 (de)	1994-10-07	1998-12-31	Novartis Ag	Oximether, sowie diese enthaltende Pflanzenschutzmittel.
US5902726A (en)	1994-12-23	1999-05-11	Glaxo Wellcome Inc.	Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US6022897A (en)	1995-04-25	2000-02-08	The Salk Institute For Biological Studies	Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
AU5701896A (en) *	1995-06-02	1996-12-18	Sankyo Company Limited	Aromatic oxyimino derivatives
US5939442A (en)	1995-06-07	1999-08-17	The Salk Institute For Biological Studies	Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
FR2737893B1 (fr) *	1995-08-16	1997-09-12	Roussel Uclaf	Nouvelles cephalosporines comportant en position 7, un radical benzyloxyimino substitue, leur procede et intermediaires de preparation, leur application comme medicaments
GB9600464D0 (en)	1996-01-09	1996-03-13	Smithkline Beecham Plc	Novel method
GB9604242D0 (en) *	1996-02-28	1996-05-01	Glaxo Wellcome Inc	Chemical compounds
JPH09323929A (ja)	1996-04-02	1997-12-16	Sankyo Co Ltd	オキシム誘導体を含有する医薬
AU708919B2 (en)	1996-04-04	1999-08-19	Sankyo Company Limited	Phenylalkylcarboxylic acid derivatives
WO1998005331A2 (en)	1996-08-02	1998-02-12	Ligand Pharmaceuticals Incorporated	Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
JP4427825B2 (ja)	1997-07-24	2010-03-10	アステラス製薬株式会社	コレステロール低下作用を有する医薬組成物
JPH11193272A (ja)	1997-10-01	1999-07-21	Sankyo Co Ltd	フェニルアルキルカルボン酸誘導体を含有する医薬
SK16412000A3 (sk) *	1998-05-11	2001-08-06	Takeda Chemical Industries, Ltd.	Deriváty kyseliny oxyiminoalkánovej

1999
- 1999-05-10 SK SK1641-2000A patent/SK16412000A3/sk unknown
- 1999-05-10 AU AU36297/99A patent/AU766831B2/en not_active Ceased
- 1999-05-10 MY MYPI99001832A patent/MY123337A/en unknown
- 1999-05-10 HU HU0103714A patent/HUP0103714A3/hu unknown
- 1999-05-10 EP EP99918355A patent/EP1077957B1/en not_active Expired - Lifetime
- 1999-05-10 PT PT99918355T patent/PT1077957E/pt unknown
- 1999-05-10 CN CNB998060070A patent/CN1148361C/zh not_active Expired - Fee Related
- 1999-05-10 PL PL99344002A patent/PL344002A1/xx not_active Application Discontinuation
- 1999-05-10 ID IDW20002324A patent/ID28699A/id unknown
- 1999-05-10 NZ NZ508066A patent/NZ508066A/xx unknown
- 1999-05-10 DE DE69919156T patent/DE69919156T2/de not_active Expired - Lifetime
- 1999-05-10 ES ES99918355T patent/ES2226377T3/es not_active Expired - Lifetime
- 1999-05-10 WO PCT/JP1999/002407 patent/WO1999058510A1/en not_active Application Discontinuation
- 1999-05-10 BR BR9910371-0A patent/BR9910371A/pt not_active IP Right Cessation
- 1999-05-10 KR KR10-2000-7000081A patent/KR100388120B1/ko not_active IP Right Cessation
- 1999-05-10 RU RU2000131183/04A patent/RU2213738C2/ru not_active IP Right Cessation
- 1999-05-10 AR ARP990102190A patent/AR029876A1/es unknown
- 1999-05-10 CA CA002331879A patent/CA2331879A1/en not_active Abandoned
- 1999-05-10 AT AT99918355T patent/ATE272625T1/de not_active IP Right Cessation
- 1999-05-10 US US09/423,854 patent/US6251926B1/en not_active Expired - Fee Related
- 1999-05-10 EP EP04075569A patent/EP1428531A1/en not_active Withdrawn
- 1999-05-10 IL IL13947099A patent/IL139470A0/xx unknown
- 1999-05-11 PE PE1999000393A patent/PE20000625A1/es not_active Application Discontinuation
- 1999-05-11 CO CO99029123A patent/CO5040066A1/es unknown
- 1999-12-28 JP JP11373202A patent/JP2000198772A/ja active Pending
2000
- 2000-11-01 LV LVP-00-148A patent/LV12606B/en unknown
- 2000-11-02 NO NO20005531A patent/NO317426B1/no unknown
- 2000-11-16 US US09/714,699 patent/US6495581B1/en not_active Expired - Fee Related
2001
- 2001-08-15 HK HK01105750A patent/HK1034972A1/xx not_active IP Right Cessation
2002
- 2002-12-27 US US10/331,056 patent/US6924300B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US6495581B1 (en)	2002-12-17
AU3629799A (en)	1999-11-29
SK16412000A3 (sk)	2001-08-06
US6251926B1 (en)	2001-06-26
JP2000198772A (ja)	2000-07-18
LV12606A (lv)	2001-01-20
EP1077957B1 (en)	2004-08-04
ES2226377T3 (es)	2005-03-16
DE69919156T2 (de)	2005-11-03
HUP0103714A2 (hu)	2002-01-28
CA2331879A1 (en)	1999-11-18
US20030186985A1 (en)	2003-10-02
CN1300285A (zh)	2001-06-20
NZ508066A (en)	2003-03-28
AR029876A1 (es)	2003-07-23
MY123337A (en)	2006-05-31
IL139470A0 (en)	2001-11-25
HUP0103714A3 (en)	2003-05-28
AU766831B2 (en)	2003-10-23
NO317426B1 (no)	2004-10-25
CO5040066A1 (es)	2001-05-29
NO20005531L (no)	2001-01-05
KR100388120B1 (ko)	2003-06-18
NO20005531D0 (no)	2000-11-02
KR20010021523A (ko)	2001-03-15
CN1148361C (zh)	2004-05-05
ATE272625T1 (de)	2004-08-15
ID28699A (id)	2001-06-28
WO1999058510A1 (en)	1999-11-18
RU2213738C2 (ru)	2003-10-10
PT1077957E (pt)	2004-10-29
EP1428531A1 (en)	2004-06-16
DE69919156D1 (de)	2004-09-09
BR9910371A (pt)	2001-01-09
EP1077957A1 (en)	2001-02-28
PE20000625A1 (es)	2000-07-24
PL344002A1 (en)	2001-09-10
HK1034972A1 (en)	2001-11-09
US6924300B2 (en)	2005-08-02

Publication	Publication Date	Title
US6495581B1 (en)	2002-12-17	Oxyiminoalkanoic acid derivatives
EP1228067B1 (en)	2004-07-14	5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
US7238716B2 (en)	2007-07-03	Alkanoic acid derivatives process for their production and use thereof
EP1394154A1 (en)	2004-03-03	Five-membered heterocyclic alkanoic acid derivative
JP4148681B2 (ja)	2008-09-10	アルカン酸誘導体、その製造法および用途
EP1229026A1 (en)	2002-08-07	Alkoxyiminoalkanoic acid derivatives
JP3074532B2 (ja)	2000-08-07	オキシイミノアルカン酸誘導体
MXPA00010576A (en)	2001-09-07	Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
CZ20004104A3 (cs)	2001-04-11	Deriváty kyseliny oxyiminoalkanové